KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Common Equity: 2009-2024

Historic Common Equity for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $3.3 million.

  • Rigel Pharmaceuticals' Common Equity rose 903.56% to $117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.6 million, marking a year-over-year increase of 903.56%. This contributed to the annual value of $3.3 million for FY2024, which is 111.48% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Common Equity of $3.3 million as of FY2024, which was up 111.48% from -$28.6 million recorded in FY2023.
  • Rigel Pharmaceuticals' 5-year Common Equity high stood at $34.0 million for FY2020, and its period low was -$28.6 million during FY2023.
  • Moreover, its 3-year median value for Common Equity was -$13.6 million (2022), whereas its average is -$13.0 million.
  • In the last 5 years, Rigel Pharmaceuticals' Common Equity crashed by 144.83% in 2022 and then surged by 111.48% in 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' Common Equity (Yearly) stood at $34.0 million in 2020, then declined by 10.73% to $30.4 million in 2021, then tumbled by 144.83% to -$13.6 million in 2022, then plummeted by 110.37% to -$28.6 million in 2023, then surged by 111.48% to $3.3 million in 2024.